Chemo-immunotherapy before surgery for stage III lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests combining chemotherapy with immunotherapy before surgery for people with stage III non-small cell lung cancer that has a PD-L1 level of 1% or higher. The goal is to see if this approach can improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stage III non-small cell lung cancer that hasn't spread to other parts of the body.
- Your tumor has a PD-L1 level of 1% or higher (a protein that may help the immunotherapy work).
- You do not have certain gene changes (EGFR, ALK, ROS1, or RET) in your tumor.
- You are healthy enough to have surgery and chemotherapy, with good lung and organ function.
- You have not had any previous treatment for this lung cancer, including chemotherapy or radiation.
- You are 18 years or older and can give informed consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests an “immunotherapy” medicine given before surgery for stage III non-small cell lung cancer. The goal is to shrink the cancer and make curative surgery more successful while monitoring safety and response.
This trial tests a combination of three drugs (tislelizumab, anlotinib, and standard chemotherapy) given before and after surgery for people with stage II to IIIB non-small cell lung cancer that does not have certain gene mutations. The goal is to see if this approach can improve outcomes for patients who can have their tumor removed.
This trial tests giving toripalimab plus another treatment (JS004) together with standard chemotherapy before lung surgery for stage IIIB–IIIC non-small cell lung cancer. It may help shrink the tumor and make surgery more effective, and it compares different treatment combinations.
This trial tests combining two immunotherapy drugs (anti-CTLA-4 antibody and sintilimab) with chemotherapy before surgery for stage II-III non-small cell lung cancer. The goal is to see if this approach helps shrink tumors and improve outcomes.
This trial tests whether giving an immune-boosting drug (Tα1) along with chemotherapy and immunotherapy before surgery helps people with stage II-IIIB non-small cell lung cancer that can be removed. It aims to see if this combination makes the cancer shrink more and improves outcomes.
This trial tests whether giving chemotherapy plus immunotherapy before surgery can help shrink stage 3 lung cancer and improve outcomes. The goal is to make the tumor easier to remove and possibly lower the chance of it coming back.
Hear when a new Stage III NSCLC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.